Last reviewed · How we verify
Nepafenac 0.1%
At a glance
| Generic name | Nepafenac 0.1% |
|---|---|
| Also known as | Nevanac |
| Sponsor | Alcon Research |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Comparative Analysis of the Effectiveness of Nepafenac Combined With a Lubricant Versus a Lubricant Alone in the Treatment of Epiphora Associated With Lacrimal Punctum Stenosis (PHASE4)
- Comparing Efficacy of Bromfenac 0.09%, Nepafenac 0.3% and Diclofenac 0.1% in Patients After Cataract Surgery (NA)
- Effects of 0.1% Nepafenac on Vitreous Inflammatory Biomarkers in Rhegmatogenous Retinal Detachment and Proliferative Vitreoretinopathy (PHASE4)
- NSAID Phase II for Non-central Involved Diabetic Macular Edema (DME) (PHASE2)
- Effect of Topical Nepafenac in Macular Thickening Related to Pan-retinal Photocoagulation (PHASE2)
- CHED - Congenital Hereditary Endothelial Dystrophy: New Paradigm Shift in Therapy Using Topical Eye Drops (PHASE2)
- Macular Edema Nepafenac vs. Difluprednate Uveitis Trial (PHASE4)
- Clinical Outcomes of Bromday (Bromfenac Ophthalmic Solution) 0.09% QD vs. Nevanac (Nepafenac Ophthalmic Suspension) 0.1% (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nepafenac 0.1% CI brief — competitive landscape report
- Nepafenac 0.1% updates RSS · CI watch RSS
- Alcon Research portfolio CI